Your browser doesn't support javascript.
loading
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset.
Langer, Thorsten; Clemens, Eva; Broer, Linda; Maier, Lara; Uitterlinden, André G; de Vries, Andrica C H; van Grotel, Martine; Pluijm, Saskia F M; Binder, Harald; Mayer, Benjamin; von dem Knesebeck, Annika; Byrne, Julianne; van Dulmen-den Broeder, Eline; Crocco, Marco; Grabow, Desiree; Kaatsch, Peter; Kaiser, Melanie; Spix, Claudia; Kenborg, Line; Winther, Jeanette F; Rechnitzer, Catherine; Hasle, Henrik; Kepak, Tomas; van der Kooi, Anne-Lotte F; Kremer, Leontien C; Kruseova, Jarmila; Bielack, Stefan; Sorg, Benjamin; Hecker-Nolting, Stefanie; Kuehni, Claudia E; Ansari, Marc; Kompis, Martin; van der Pal, Heleen J; Parfitt, Ross; Deuster, Dirk; Matulat, Peter; Tillmanns, Amelie; Tissing, Wim J E; Beck, Jörn D; Elsner, Susanne; Am Zehnhoff-Dinnesen, Antoinette; van den Heuvel-Eibrink, Marry M; Zolk, Oliver.
Afiliación
  • Langer T; Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
  • Clemens E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Broer L; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Maier L; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Uitterlinden AG; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Medical Center, Ulm, Germany.
  • de Vries ACH; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van Grotel M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Pluijm SFM; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Binder H; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Mayer B; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • von dem Knesebeck A; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Byrne J; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
  • van Dulmen-den Broeder E; Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
  • Crocco M; Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
  • Grabow D; Boyne Research Institute, Drogheda, Ireland.
  • Kaatsch P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kaiser M; Department of Pediatric Hematology and Oncology, VU Medical Center, Amsterdam, The Netherlands.
  • Spix C; Department of Neurooncology, Istituto Giannina Gaslini, Genova, Italy.
  • Kenborg L; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Winther JF; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Rechnitzer C; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Hasle H; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Kepak T; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.
  • van der Kooi AF; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.
  • Kremer LC; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
  • Kruseova J; Copenhagen University Hospital Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark.
  • Bielack S; Aarhus University Hospital, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
  • Sorg B; University Hospital Brno, Brno, Czech Republic, & International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic.
  • Hecker-Nolting S; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kuehni CE; Department of Obstetrics and Gynecology, Erasmus MC - Sophia Children's Hospital, The Netherlands.
  • Ansari M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kompis M; Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
  • van der Pal HJ; Department of Children Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic.
  • Parfitt R; Department of Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
  • Deuster D; Department of Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
  • Matulat P; Department of Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
  • Tillmanns A; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Tissing WJE; Paediatric Oncology, Dept. of Paediatrics, Inselspital, University of Bern, Switzerland.
  • Beck JD; Department of Pediatrics, Oncology and Hematology Unit, University Hospital of Geneva, Cansearch Research Laboratory, Geneva University, Switzerland.
  • Elsner S; Department of Otolaryngology, Head and Neck Surgery, Inselspital, University of Berne.
  • Am Zehnhoff-Dinnesen A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Zolk O; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
Data Brief ; 32: 106227, 2020 Oct.
Article en En | MEDLINE | ID: mdl-32939381
Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patients were assigned to three phenotype categories: no, minor, and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1, and ACYP2) were genotyped. The genotype and phenotype data represent a resource for conducting meta-analyses to derive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to platinum treatment.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: Data Brief Año: 2020 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: Data Brief Año: 2020 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos